AI Article Synopsis
- Researchers aimed to understand the role of CXC chemokine ligand 10 (CXCL10) in isolated polymyalgia rheumatica (PMR) by comparing its serum levels in PMR patients before and after treatment, as well as in rheumatoid arthritis (RA) patients and healthy individuals.
- The study collected and analyzed serum samples from multiple patient groups over several years, using protein microarray technology and enzyme-linked immunosorbent assay (ELISA) to measure various cytokines, particularly focusing on CXCL10.
- Results showed that CXCL10 levels were significantly higher in active PMR patients compared to those in remission, RA patients, and healthy controls, suggesting it may be important in PMR pathogenesis and
Article Abstract
Objective: To investigate the significance of CXC chemokine ligand 10 (CXCL10) in the pathogenesis of isolated polymyalgia rheumatica (PMR).
Methods: The serum of six PMR patients diagnosed and treated at the First Affiliated Hospital of Wannan Medical College from September 2019 to December 2020 before treatment and after remission was collected, and the serum of six active rheumatoid arthritis (RA) patients and six healthy medical checkups were also collected, and protein microarray technology was used to detect 24 cytokines, including IL-6, IL-4, CXCL10, CXCL8, and CXCL2. Subsequently, serum was collected from other 28 patients with active PMR, 26 patients with PMR in remission, 24 patients with active RA, and 24 healthy medical checkups who were diagnosed and treated at the First Affiliated Hospital of Wannan Medical College from January 2021 to July 2023, and the enzyme-linked immunosorbent assay (ELISA) was used to validate and compare the levels of CXCL10 in each group and analyze the correlation between the levels of serum CXCL10 and the parameters of the clinical activities of PMR.
Results: Protein microarray screening revealed significant differences in CXCL10 before and after PMR treatment, and ELISA validation revealed that peripheral serum CXCL10 levels were significantly higher in the PMR-active group than in the remission group (P < 0.001), and also significantly higher than in the RA-active group (P = 0.003) and in the healthy control group (P < 0.001); correlation analysis showed a significant positive correlation between serum CXCL10 levels and serum ferritin in PMR patients (r = 0.450, P = 0.024). In the ROC curve for distinguishing PMR and RA, the area under the curve is 0.741, sensitivity = 0.643, and specificity = 0.792.
Conclusion: CXCL10 may play a role in the pathogenesis of isolated PMR and its level might contribute to the differential diagnosis of PMR and RA. Key Points • The concentration of CXCL10 was higher in peripheral blood of isolated PMR patients. • CXCL10 is a potential diagnostic biomarker for isolated PMR patients. • The level of CXCL10 might contribute to the differential diagnosis of PMR and RA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11582166 | PMC |
| http://dx.doi.org/10.1007/s10067-024-07209-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative analysis of arterial involvement in predominant cranial and isolated extracranial phenotypes of giant cell arteritis using F-FDG PET-CT.
Arthritis Res Ther
December 2024
Department of Rheumatology, Hospital Universitario de Bellvitge. Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
Objective: To investigate differences in arterial involvement patterns on F-FDG PET-CT between predominant cranial and isolated extracranial phenotypes of giant cell arteritis (GCA).
Methods: A retrospective review of F-FDG PET-CT findings was conducted on 140 patients with confirmed GCA. The patients were divided into two groups: the cranial group, which presented craniofacial ischemic symptoms either at diagnosis or during follow-up, and the isolated extracranial group which never exhibited such manifestations.
Infective agents and polymyalgia rheumatica: key discussion points emerging from a narrative review of published literature.
Reumatologia
November 2024
Department of Primary Care, Health District of Soverato, Azienda Sanitaria Provinciale Catanzaro, Italy.
Introduction: The aetiology of polymyalgia rheumatica (PMR) is unknown. Recently, reports on cases of PMR following the coronavirus disease 2019 (COVID-19) have revived the role of infection as an aetiological or triggering factor. It is estimated that patients with PMR have manifestations of giant cell arteritis (GCA) in < 20% of cases.
View Article and Find Full Text PDFAlkaline phosphatase is useful for predicting giant cell arthritis complications in patients with polymyalgia rheumatica.
Mod Rheumatol
November 2024
Department of General Medicine, The Jikei University School of Medicine, Daisan Hospital, Tokyo, Japan.
Objectives: This study determined whether alkaline phosphatase can be used to distinguish giant cell arthritis complications in patients with polymyalgia rheumatica.
Methods: This retrospective study included patients diagnosed with polymyalgia rheumatica between January 2014 and October 2023 at our hospital. The predictive accuracy of biomarkers for diagnosing giant cell arthritis was evaluated.
Traditional and Emerging Strategies for Managing Polymyalgia Rheumatica: Insights into New Treatments.
J Clin Med
October 2024
Division of Rheumatology, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain.
Article Synopsis
- Polymyalgia Rheumatica (PMR) is an inflammatory condition commonly affecting people over 50, with glucocorticoids being the main treatment despite their side effects and risk of relapses upon tapering.
- This review explores traditional PMR management and highlights emerging therapies, especially glucocorticoid-sparing agents like methotrexate and biologic agents, which show promise in reducing glucocorticoid use and managing the disease effectively.
- The effectiveness of biologics, particularly anti-IL-6 receptor agents such as tocilizumab and sarilumab, has been noted for their ability to decrease relapse rates and help achieve long-term remission in PMR patients.
Study on the changes and significance of CXCL10 level in serum of isolated polymyalgia rheumatica.
Clin Rheumatol
December 2024
Department of Rheumatology and Immunology, The First Affiliated Hospital of Wannan Medical College, Wuhu, China.
Article Synopsis
- Researchers aimed to understand the role of CXC chemokine ligand 10 (CXCL10) in isolated polymyalgia rheumatica (PMR) by comparing its serum levels in PMR patients before and after treatment, as well as in rheumatoid arthritis (RA) patients and healthy individuals.
- The study collected and analyzed serum samples from multiple patient groups over several years, using protein microarray technology and enzyme-linked immunosorbent assay (ELISA) to measure various cytokines, particularly focusing on CXCL10.
- Results showed that CXCL10 levels were significantly higher in active PMR patients compared to those in remission, RA patients, and healthy controls, suggesting it may be important in PMR pathogenesis and
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!